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Abstract One of the main pursuits, yet most difficult, in mon-
itoring studies is to identify the sources of environmental pol-
lution. In this study, we have identified health-care facilities
from south European countries as an important source of phar-
maceuticals in the environment. We have estimated that com-
pounds consumed in by the elderly and released from effluents
of senior residences can reach river waters at a concentration
higher than 0.01 μg/L, which is the European Medicines
Agency (EMA) threshold for risk evaluation of pharmaceuti-
cals in surface waters. This study has been based on five health
institutions in Portugal, Spain, and France, with 52 to 130
beds. We have compiled the pharmaceuticals dispensed on a
daily base and calculated the consumption rates. From 54.9 to
1801 g of pharmaceuticals are consumed daily, with laxatives,
analgesics, antiepileptics, antibiotics, and antidiabetic agents
being the main drug families administered. According to ex-
cretion rates, dilution in the sewerage system, and elimination
in wastewater treatment plants, macrogol, metformin, paracet-
amol, acetylcysteine, amoxicillin, and gabapentin, among
others, are expected to reach river waters. Finally, we discuss
the risk management actions related to the discharge of phar-
maceuticals from senior residences to surface waters.
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Introduction
Water pollution today represents a major challenge both at the
economic and social level. The quality of water must be pre-
served both for human protection and to safeguard the envi-
ronment from compounds capable of exerting an effect at low
levels of concentration. Among others, pharmaceuticals are of
concern because they are consumed in high quantities; many
are refractory to traditional wastewater treatment and thus be-
come widely distributed in river waters (Banjac et al. 2015;
Zhang et al. 2013). Their presence in the environment has
been attributed to the discharge of hospital effluents
(Gómez-Canela et al. 2014, Langford and Thomas 2009;
Santos et al. 2013; Verlicchi et al. 2010), domestic water
(Rabiet et al. 2006), and effluents from wastewater treatment
plants (WWTP) (Gómez-Canela et al. 2012; Santos et al.
2013; Verlicchi et al. 2012). This study explores senior resi-
dences and sociosanitary centers as a source of pharmaceuti-
cals to environmental waters.
Electronic supplementary material The online version of this article
(doi:10.1007/s11356-017-9755-1) contains supplementary material,
which is available to authorized users.
* Silvia Lacorte
slbqam@cid.csic.es
1 Department of Environmental Chemistry, IDAEA-CSIC, Jordi
Girona 18-26, 08034 Barcelona, Catalonia, Spain
2 Centro de Investigação e Intervenção Social (CIS-IUL), Instituto
Universitário de Lisboa (ISCTE-IUL), Lisbon, Portugal
3 EA7352 CHROME, Université de Nimes, Rue du Dr Georges Salan,
30021 Nimes, France
4 Department of Chemistry, University of Coimbra,
3004-535 Coimbra, Portugal
5 INPT; CNRS; LGC (Laboratoire de Génie Chimique), Université de
Toulouse, 4, Allée Emile Monso, 31030 Toulouse, France
6 Facultad de Psicología, Universidad Complutense de Madrid,
Madrid, Spain
7 Laboratoire Biocapteurs, Analyses, Environnement, BAE-LBBM
USR 3579, Université de Perpignan Via Domitia, 52 Av Paul Alduy,
66860 Perpignan cedex, France
In Europe and over the world, the phenomenon of aging
and over-aging has led to societies where 15–20% of the pop-
ulation is over 65 years. Part of this population reside in homes
for the elderly or in sociosanitary centers if the level of im-
pairment is high. The homes for elderly or health care institu-
tions are infrastructures that emerge in response to
biopsychosocial needs and have become popular in most
European countries. On the other hand, sociosanitary centers
provide integral attention to people that require special care
because of the low health status, either physic, psychic, or
intellectual. These establishments have a configuration of typ-
ically 50–150 beds and provide lodging, meal services, and
health and social assistance. With an estimated consumption
of 5–10 pills/patient, much higher than the healthy population,
the total consumption of pharmaceuticals is of hundreds of
milligrams. These compounds are excreted through urine or
feces and are released to the main urban sewerage system
without any type of treatment. Then, waters are transported
to the WWTP and a fraction is eliminated during primary and
secondary treatment, but depending on the configuration of
the WWTP, pharmaceuticals can also be discharged to receiv-
ing waters. Due to the aging effect and the increased popula-
tion established in homes for the elderly or health care insti-
tutions, senior residences. Thus, senior residences these estab-
lishments can represent a point source pollution of pharma-
ceuticals to the environment.
The European Medicines Agency (EMA) is an agency of
the European Union (EU), responsible for the scientific eval-
uation, supervision, and safety monitoring of medicines de-
veloped by pharmaceutical companies for use in the EU
(European Medicines Agency (EMA) 2006). Among other
activities, they monitor the safety of medicines across their
life cycle. In 2006, EMA proposed the calculation of predicted
environmental concentrations (PEC) to estimate the presence
of pharmaceuticals in environmental waters and recommend-
ed to evaluate their risk when PEC values in surface water
were equal or above the threshold value of 0.01 μg/L. This
model takes into account the consumption of a specific drug,
the excretion rates, and the dilution factor in a particular region
and permits to prioritize specific drugs with potential to cause
toxic effects at specific water concentrations (Fick et al. 2010).
The efficiency and applicability of the approach to determine
the theoretical presence of pharmaceuticals in surface waters
and wastewaters and to prioritize compounds for further mon-
itoring has been demonstrated by the increasing number of
research papers that use this methodology, as in Italy (Riva
et al. 2015), Germany (Kümmerer and Al-Ahmad 2010), NW
England (Booker et al. 2014), France (Besse et al. 2008),
Catalonia (Franquet-Griell et al. 2015), the Netherlands
(Oosterhuis et al. 2013), Spain (Ortiz de García et al. 2013)
and Poland (Oldenkamp et al. 2013). van Nuijs et al. 2015).
According to prescription data (van Nuijs et al. 2015), PEC
values and toxicological information, it is then possible to
determine the potential risk of pharmaceuticals in the environ-
ment (van Leeuwen and Vermeire 2007).
Our hypothesis is that senior residences represent an im-
portant source of pharmaceuticals to the environment. In this
study, we propose an innovative scheme for assessing the
loads and discharge of pharmaceuticals from four senior res-
idences and one sociosanitary center from France, Portugal,
and Spain. We have followed EMA guidelines for PEC cal-
culation and risk evaluation based on consumption data, ex-
cretion, dilution, and toxicity. We finally provide a list of
pharmaceuticals consumed in high quantities in senior estab-
lishments and discuss their environmental impact.
Methodology
Health Institutions studied
Health Institutions can be classified in different categories,
each with its own specialization, particularity, and function-
ing, as they host people with different types of illnesses. In this
study, we have selected five establishments, one in France,
two in Spain, and two in Portugal. For comparability purposes
among the three countries, the establishments selected had a
high number of beds (>50) and were located in urban areas.
Selected establishments were (i) residences oriented to hous-
ing or day care for independent individuals that do not require
help or assistance and also general impairment (for individuals
with general loss of activities of daily function) and (ii) a
sociosanitary center which has a high level of impairment.
The detailed description of each residence (number of beds,
type of facility, and the annual water consumption) is indicat-
ed in Table 1.
In each establishment, we interviewed the manager and the
head health professional to obtain information on the type of
patients, sickness, and level of impairment. All this informa-
tion was key to defining the typology of the residence and
treatments performed. Then, each establishment provided
complete data on the consumption of pharmaceuticals, as the
number of pills, injections or other presentations of a specific
drug, and their concentration. This information was compiled
to identify the main pharmaceutical families administered and
to calculate the total amount consumed (milligrams per day) in
each establishment (Table 2). To compare the consumption
rates in the five establishments, consumption data was nor-
malized per patient so that data is given also in milligrams
per day per patient. Data correspond to consumptions in
2015, except for F1 and S1 which correspond to 2016.
Estimation of the predicted environmental concentrations
PEC calculations were adapted from EMA guidelines to de-
termine the predicted concentrations in effluents from senior
residences (PECres), the predicted concentration in the sew-
erage system (PECgrid), and the predicted concentrations in
river (PECriv). The former permitted to determine pharmaceu-
ticals released from health-care establishments according to
high consumption and high excretion. On the other hand,
PECgrid considered the dilution of the effluent from the
health-care facilities to the urban sewerage system. Finally,
PECriv considered the elimination in WWTP and the final
dilution in receiving waters. PEC values are always given in
micrograms per liter.
When calculating PECres, one of the main particulari-
ties that might affect the discharge of pharmaceuticals is
the people wearing diapers. This implies that an inferior
amount of pharmaceuticals than the one that was actually
consumed will be discharged. This factor is included in the
PECres formula:
PECres ¼
DRUGconsumption  FExcretion  1−FPadsð Þ
WATERconsumption
 106 ð1Þ
where
– DRUGconsumption (g/day) is the quantity of each pharma-
ceutical delivered in each senior residence.
– FExcretion is the excreted fraction of the unchanged drug,
considering both urine and feces. Excretion data was ob-
tained from Theriaque database (Amiel and Husson,
1994). Selected values ranged from negligible to 100%,
depending on the compound.
– FPads is the percentage of patients using incontinence
pads. In this study, we used the value of 50% as it repre-
sents the mean percentage of patients using incontinence
pads in the establishments studied.
– WATERconsumption (L/day) is the water consumed in each
residence per patient per year (Table 1).
– 106 is a conversion factor so that PECres are expressed in
micrograms per liter.
To evaluate the amount of pharmaceuticals discharged to
the river waters, PECriv (in μg/L) were estimated using the
formulas:
PECgrid ¼
PECres
DFGRID
ð2Þ
PECriv ¼ PECgrid
1−FWWTPð Þ
DFRIVER
ð3Þ
where
– DFGrid is an expected dilution factor from senior resi-
dences to the general sewage grid. To calculate this
factor, we determined the percentage of water from
senior establishment to the general volume of water
in the sewerage system. In Barcelona and Lisbon, the
dilution factor is more than 2500, and in Nimes of
1300 times, based on the volume of sewage water in
each sewerage system collected in each treatment plant
(27,000 m3/day in Nimes, 450,000 m3/day in Barcelona,
350,000 m3/day in Lisbon). We used an agreement value
of 100 times for all three sites considering that the total
sewage water is divided in 5-10 collectors in each city and
the flow can vary substantially according to discharges,
rains, etc..
– FWWTP is the removal fraction in WWTP. Removal data
was obtained from EPI Suite by Environmental
Protection Agency (EPA) (EPA 2013). Here, when dif-
ferent data were obtained from the bibliography, the
lowest value was applied. In the cases that no informa-
tion was available, a default value of 0 was used indi-
cating that a given compound is not eliminated.
– DFRIVER is the dilution factor from WWTP effluents to
receiving water and was considered 75.73 for France,
25.92 for Spain, and 61.23 for Portugal, as suggested by
Keller et al. (2014). This differential dilution factor is
used to better estimate PEC values according to the dif-
ferences in river flows and dynamics among countries.
For compounds with PECriv >0.01 μg/L, as proposed
by EMA, the toxicity data was compiled according to
ECOTOX (EPA), DrugBank, or toxicological data sheets
of Sigma-Aldrich, ScienceLab, and Santa Cruz
Biotechnology.
Table 1 Number of pharmaceuticals administered in five establishments for the elderly according to consumption data in 2015 and 2016
Residence Size Facility type Water consumption
(m3/year)
Pharmaceuticals
administered
Beds Day center
F1 75 6 Housing and general impairment 4560 133
S1 100 30 Sociosanitary center, general impairment, and psychiatric unit 6679 164
S2 130 0 Housing, general impairment 7100 134
P1 52 0 Housing, general impairment 5230 116
P2 61 0 Housing, general impairment 4859 146
Table 2 Pharmaceuticals administered in each residence ordered by consumption data (>1000 mg/day, > 400 mg/day in France given the overall low
consumptions), PECres, PECgrid, and PEC river
Pharmaceutical ATC code Category Consumption
(mg/day)
Excretion (%) PECres (μg/L),
50% of diapers
PECgrid (μg/L),
100% DF
PEC river
(μg/L)
Residence F1 (81 beds)
Paracetamol N02BE01 Analgesic 27233 5 54.5 0.545 0.007
Metformin A10BA02 Antidiabetic 4355 77 134 1.342 0.017
Levetiracetam N03AX14 Antiepileptic 2043 66 54.0 0.540 0.007
Amiodarone C01BD01 Antiarrhytmic 815 0.5 0.16 0.002 0.000
Irbesartan C09CA04 Antihypertensive 735 31 9.13 0.091 0.001
Furosemide C03CA01 Diuretic 595 0.5 11.9 0.119 0.002
Acebutolol C07AB04 β-blokers 594 50 7.14 0.071 0.001
Amoxicillin J01CA04 Antibiotic 547 30 16.2 0.162 0.002
Dabigatran etexilate B01AE07 Anticoagulant 463 74 16.7 0.167 <0.001
Tramadol N02AX02 Analgesic 405 90 4.86 0.048 <0.001
Sociosanitary center S1 (130 beds)
Macrogol A06AD15 Laxative 581336 100 15885 158 6.015
Paracetamol N02BE01 Analgesic 166329 5 227 2.272 0.086
Metamizole N02BB02 Analgesic 24486 0.5 3.35 0.033 0.001
Metformin A10BA02 Antidiabetic 17466 77 367 3.675 0.139
Acetylcysteine R05CB01 Mucolytic 13151 50 180 1.797 0.069
Amoxicillin J01CA04 Antibiotic 9897 70 189 1.893 0.072
Valproic acid N03AG01 Antiepileptic 8603 3.2 7.52 0.075 0.003
Gabapentin N03AX12 Antiepileptic 7781 100 213 2.126 0.081
Ibuprofen M01AE01 NSAID* 5753 10 15.7 0.157 0.004
Acetylsalicylic acid N02BA01 Analgesic 5562 10 15.2 0.152 0.006
Quetiapine N05AH04 Antipsychotic 4422 5 6.04 0.060 0.002
Clomethiazole N05CM0 Hypnotic 3314 5 4.53 0.045 0.002
Cyanocobalamine V09XX01 Vitamin 2795 90 68.7 0.687 0.027
Pyridoxine (vit B6) A11HA02 Vitamin 2795 0.5 009 0.004 0.000
Levetiracetam N03AX14 Antiepileptic 2466 66.3 44.7 0.447 0.017
Trazodone N06AX05 Antidepressant 2466 0.13 0.09 0.001 <0.001
Sulfamethoxazole J01EC01 Antibiotic 2301 20 12.6 0.126 0.005
Ascorbic acid A11GA Vitamin 2178 2.6 1.55 0.015 0.001
Oxerutin C05CA02 Vasoprotector 1973 24.2 13.0 0.130 0.005
Furosemide C03CA01 Diuretic 1779 50 24.3 0.243 0.009
Levofloxacin J01MA12 Antibiotic 1644 85 38.2 0.382 0.014
Omeprazole A02BC01 Antiulcer 1617 20 8.84 0.088 0.003
Oxcarbazepine N03AF02 Antiepileptic 1315 1 0.36 0.004 0.000
Mupirocin D06AX09 Antibiotic 1216 4.6 1.53 0.015 0.001
Carbamazepine N03AF01 Antiepileptic 1096 1 0.30 0.003 <0.001
Megestrol G03DB02 Sex hormone 1056 86 24.8 0.248 0.007
Spironolactone C03DA01 Antihypertensive 1045 0.5 0.14 0.001 <0.001
Residence S2 (130 beds)
Insulin A10AB Insulins 396279 1 83.3 0.833 0.032
Lactitol A06AD12 Laxative 150874 1.4 44.4 0.444 0.017
Macrogol A06AD15 Laxative 57729 100 1213 12.13 0.459
Paracetamol N02BE01 Analgesic 16912 5 17.7 0.178 0.007
Metformin A10BA02 Antidiabetic 8269 77 134 1.338 0.051
Valproic acid N03AG01 Antiepileptic 5768 3.2 3.88 0.039 0.001
Trazodone N06AX05 Antidepressant 4742 0.13 0.13 0.001 <0.001
Prioritization and risk evaluation
It is not feasible to monitor all possible pharmaceuticals
present in the environment, and it is necessary to priori-
tize those that can represent the greatest threat (Donnachie
et al. 2016). The consumption data permitted to prioritize
compounds with the highest potential impact in river wa-
ters from France, Spain, and Portugal. The workflow used
is based on
1. Listing of pharmaceuticals according to the consumed
data in each senior residence.
Table 2 (continued)
Pharmaceutical ATC code Category Consumption
(mg/day)
Excretion (%) PECres (μg/L),
50% of diapers
PECgrid (μg/L),
100% DF
PEC river
(μg/L)
Carvedilol C07AG02 β-blokers 3146 2 1.32 0.013 0.001
Levodopa N04BA01 Antiparkinsonian 2928 10.5 6.46 0.065 0.002
Levetiracetam N03AX14 Antiepileptic 2625 66.3 36.6 0.366 0.014
Quetiapine N05AH04 Antipsychotic 2506 5 2.63 0.026 0.001
Acetylsalicylic acid N02BA01 Analgesic 2021 10 4.25 0.042 0.002
Furosemide C03CA01 Diuretic 1344 50 14.1 0.141 0.005
Gabapentin N03AX12 Antiepileptic 1200 100 25.2 0.252 0.010
Pentoxifylline C04AD03 Vasodilator 1200 1 0.25 0.003 <0.001
Phenytoin N03AB02 Antiepileptic 1050 1 0.22 0.002 <0.001
Troxerutin C05CA04 Vasoprotector 1033 65 14.1 0.141 0.005
Residence P1 (52 beds)
Metformin A10BA02 Analgesic 12025 77 323 3.231 0.052
Paracetamol N02BE01 Antiparkinsonian 8975 5 15.6 0.157 0.003
Levodopa N04BA01 Analgesic 3900 10.5 14.3 0.143 0.002
Acetylsalicylic acid N02BA01 Analgesic 3771 10 13.2 0.132 0.002
Glucosamine M01AX05 Antiulcer 3000 21.3 22.3 0.223 0.004
Sucralfate A02BX02 Antiepileptic 3000 0.5 0.52 0.005 <0.001
Valproic acid N03AG01 Antiepileptic 2750 0.5 0.48 0.005 <0.001
Tiotropium bromide R03BB04 vasculoprotector 2000 74 51.6 0.516 0.008
Diosmin C05CA03 Antidepressant 1800 7 4.40 0.044 0.001
Sertraline N06AB06 Antidepressant 1200 0.2 0.08 0.001 <0.001
Ibuprofen M01AE01 NSAID* 1200 10 4.19 0.042 0.001
Levodopa N04BA01 Antiparkinsonian 1025 30 10.7 0.107 0.002
Levetiracetam N03AX14 Antiepileptic 1000 66.3 23.1 0.231 0.004
Residence P2 (61 beds)
Macrogol A06AD15 Laxative 13125 100 492 4.930 0.079
Paracetamol N02BE01 Analgesic 17600 5 33.1 0.331 0.005
Metformin A10BA02 Antidiabetic 5425 77 156 1.569 0.026
Glucosamine M01AX05 Analgesic 4500 21.3 36.0 0.360 0.006
Diosmin C05CA03 vasculoprotector 4500 7 11.8 0.118 0.002
Metamizole N02BB02 Analgesic 4025 0.5 0.76 0.008 <0.001
Piracetam N06BX03 Psychostimulant 3600 100 135 1.352 0.022
Pentoxifylline C04AD03 Vasodilator 2000 1 0.75 0.008 <0.001
Acetylsalicylic acid N02BA01 Analgesic 1850 10 6.95 0.069 0.001
Levetiracetam N03AX14 Antiepileptic 1600 66.3 39.8 0.398 0.007
Valproic acid N03AG01 Antiepileptic 1600 3.2 3.12 0.031 0.001
Allopurinol M04AA01 Hypo-uricemic 1450 8 4.36 0.044 0.001
Trazodone N06AX05 Antidepressant 1275 0.13 0.06 0.001 <0.001
Sulfasalazine A07EC01 Antiinflammatory 1000 5 1.88 0.019 <0.001
*Nonsteroidal anti-inflammatory drugs
2. Calculation of the predicted concentration in the effluents
of the senior residence (PECres) for all compounds and all
residences.
3. Calculation of PEC in river waters and ranking of com-
pounds with PECriv higher than the 0.01-μg/L threshold
level proposed by EMA.
4. Toxicity evaluation using Daphnia magna or other spe-
cies EC50 or LC50 values, depending on available data.
5. Selection of toxic compounds for which risk assessment is
needed.
All this information has been compiled in a database that
allows to identify those substances discharged from health-
care facilities that may produce an environmental effect.
Results
Consumption of pharmaceuticals
Figure 1 shows the consumption of pharmaceuticals in the
five senior residences located in France, Spain, and Portugal.
The net total amount of pharmaceuticals ranged between 54
and 1801 g/day, with the residences in Spain being the ones
with the highest consumption. According to the size of each
residence, this corresponds to an average consumption per day
per person ranged from 677 mg in F1 to 13,856 and 9755 mg
in S1 and S2, respectively, although the levels were quite
similar in P1 and P2 (between 1279 and 1714 mg/person/
day). Considering these quantities and taking into account that
senior residences have become a living preference in many
countries, the amounts of pharmaceuticals discharged to the
sewerage system can become a real problem. For instance,
there are >8000 public senior residences in France, 5339 in
Spain, and 4787 in Portugal, besides the number of
sociosanitary centers, which suggests that the estimated total
consumption of pharmaceuticals from senior residences
should not be disregarded in terms of contribution of pharma-
ceutical load to the sewerage system and indirectly, to the
environment. A rough estimation average discharge considers
a consumption of 100 g/day in a median residence of 100
patients, which would mean than on a country base, from
478 to 800 kg of pharmaceuticals are discharged daily from
health institutions in south-west Europe. These figures are
similar to those reported in Germany (Herrmann et al. 2015).
Thus, the incurred impact on WWTP or rivers can be high. In
comparison, the potential discharge of pharmaceuticals from
the normal healthy population dwelling in an urban area is
much lower as consumption is not in such high amounts and
discharge is not concentrated in time or space.
The number of pharmaceuticals consumed in each senior
residence ranged between 116 and 164 (Table 1). Main phar-
maceuticals consumed (>1000 mg/day, 400 mg/day in F1) in
each of the five studied residences are indicated in Table 2.
Observed differences in main consumed drugs in French,
Spanish, and Portuguese residences evidenced the different
and specific treatments that patients can receive. A total of
397 common pharmaceuticals were consumed in the five se-
nior residences studied, which belong to 90 therapeutic clas-
ses. Table SI1 shows all pharmaceuticals consumed in the five
senior residences studied, indicating their Anatomical
Therapeutic Chemical (ATC) classification code (WHO
2017). On the other hand, the main therapeutic classes con-
sumed are indicated in Fig. 2 and include antidiabetic agents,
analgesics, antibiotics, and antiepileptics as the main treat-
ments for the elderly. Figures 1 and 2 also show the high
variability of each therapeutic group consumed in the three
countries, reflecting specific treatments according to the dif-
ferent health problems in each establishment or either specific
medication according to impairment intrinsic of each patient
or typology of residence.
Flow of pharmaceuticals from senior residences to river
waters
Of the total number of pharmaceuticals consumed, we deter-
mined the PEC values in the effluents of senior residences.
These calculations took into account that approximately half
of the people living in the residences wear incontinency pads.
At a glance, this appears to minimize the problem of pharma-
ceuticals discharged into the wastewaters. However, it is im-
portant to note that this is adding up to another problem. If
diapers are not properly disposed as biohazard waste in the
senior residences, a similar amount of residues is polluting
other places, e.g., landfills.
Among the total 397 pharmaceuticals administered in all
residences, Table 2 indicates those with amounts administered
in quantities higher than 1000 mg/day (400 mg/day in
France). PECres varied from negligible to hundreds of micro-
grams per liter (Table 2). Given the large number of pharma-
ceuticals administered, it is obvious that the ones consumed at
the highest concentration and showing high excretion rates
will have higher chances to reach surface waters. We observed
that compounds consumed in amounts >1000 mg can be
discharged to the sewerage system, and even they are diluted
and biodegraded in the WWTP, and they can reach receiving
surface waters at the nanogram per liter level. This process of
dilution and elimination of pharmaceuticals in WWTP would
presumably lead to a concentration in river waters close to the
EMA value of 0.01 μg/L. Only 20 had PECriv >0.01 μg/L,
with 1 being for F1, 9 for S1, 6 for S2, 1 for P1, and 3 for P2.
Table 2 indicates these compounds.
PECriv are also indicated in Table 2 and ranged between
0.001 and 6.15 μg/L, with the highest levels found in Spain
due to the lower dilution factor. Comparing PECres and
PECriv, the concentrations estimated in river waters represent
on average 0.01% or less of the initially discharged by the
effluents of the health-care establishments. This decrease in
concentration is basically due to 100× dilution in the sewerage
system and dilution in river. The WWTP degradability for
most of the compounds was very low, and thus, a high pro-
portion of pharmaceuticals will be potentially discharged by
the WWTP effluents to receiving waters. Figure 3 shows,
using a double axis, this difference. For the studied com-
pounds, the percentage of pharmaceuticals detected in river
is low in comparison to the effluents of the residences, indi-
cating that dilution is the main process for the removal of
pharmaceuticals once discharged to the sewerage system.
In France, only one compound, metformin, had PECres of
134 μg/L and PECriv of 0.017 μg/L, which represents
0.013% of the concentration initially discharged given a high
excretion rate. Paracetamol had high PECres but was highly
eliminated in WWTPs and thus had low PECriv. Dabigatran
and amoxicillin were highly biodegradable inWWTP, and the
rest of the compounds are expected to be found in the effluents
of the WWTP, but once diluted to the river their concentration
is expected to be at the low nanogram per liter level.
In both Spanish residences, 15 compounds exceeded the
EMA threshold value (0.01 μg/L). PECriv ranged from 0.01
to 0.086 μg/L, except for macrogol which had PECriv from
0.459 to 6.015 μg/L. Macrogol is the international nonpropri-
etary name for polyethylene glycol used primarily as laxative or
also as excipient in many pharmaceutical products. It is con-
sumed in high amounts in Spain (57–581 g/day in the two
Spanish residences or from 0.5 to 5 g/inhab/day) and is rapidly
excreted and poorly biodegraded inWWTP.WWTP were only
Fig. 1 Total daily consumption
of pharmaceuticals in each
residence, indicating the number
of residents (N) and the families
consumed in each establishment
(pie diagrams)
Fig. 2 Families of
pharmaceuticals (in percentage)
most widely consumed in health
institutions from southwest
Europe (France, Spain, and
Portugal). N indicates the number
of pharmaceuticals dispensed for
each family. Macrogol (laxative)
is not represented as its con-
sumption ranges from 13 to
580 g/day which would represent
86% of the total pharmaceuticals
consumed
partially efficient in eliminating ibuprofen (29%) and megestrol
(30%), but despite the high PECres, they would not be expected
to be found in river waters if originating only from health-care
facilities. However these compounds are widely used by the
overall population and frequently detected in river waters (van
Nuijs et al. 2015). Overall, in Spanish residences, compounds
with the highest PECriv were macrogol, paracetamol, metfor-
min, acetylcysteine, amoxicillin gabapentin, cyanocobalamin,
levetiracetam, levofloxacin, and megestrol. The low dilution
factor is mainly responsible for the high PECriv of these
compounds.
Finally, in Portugal one compounds in P1 and 3 in P2 were
consumed in amounts which produced PECriv higher than the
EMA 0.01 μg/L threshold value (Table 2), indicating that
despite the high dilution factor compared to Spain (61.23 vs
25.92), the pharmaceuticals consumed in senior residences
might contribute to river water contamination. In Portugal,
the compounds with the highest PECriv were macrogol, met-
formin, and piracetam.
When estimating PECriv for compounds with consumption
of 1000 mg/day, we observed that dilution in the sewerage
system, elimination in the WWTP, and dilution in river waters
may not be enough to eliminate all pharmaceuticals. We have
then identified that some compounds present in effluents
would be presumably detected in river waters at levels of
0.01–6.15 μg/L. The compounds that should be considered
as suspect compounds as they could be present in river waters
at concentrations >0.01 μg/L are indicated in Table 2 for each
establishment.
Considering the three countries, the most consumed drugs
and for which PECriv is higher than 0.01 μg/L proposed by
EMA are listed in Table 2. Altogether, 12 compounds of the
397 commonly administered in health institutions had PECriv
>0.01 μg/L. Of these, only metformin was common in all
countries. The rest of the compounds are specific of a given
country or even health institution, indicating that there is a
wide variability on the pharmaceuticals administered to pa-
tients, even though most belong to the same family. Many of
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these compounds have been previously identified as most
commonly detected in the environment. For instance, metfor-
min has been previously identified as one of the main phar-
maceuticals in wastewaters in the Netherlands (Oosterhuis
et al. 2013). Similarly, Van Nuijs et al. detected metformin,
valsartan, and tramadol in sewage water with good correlation
with prescribed values (van Nuijs et al. 2015). In Iraq, para-
cetamol, amoxicillin, and metformin had an annual consump-
tion exceeding 1000 t per year and were expected to produce a
risk (Al-Khazrajy and Boxall 2016).
Prioritization of pharmaceuticals for further treatment
and risk assessment
Table 3 gives the physico-chemical characteristics of the pri-
oritized pharmaceuticals according to PECriv >0.01 μg/L
EMA threshold and includes also common phramaceuticals
in the 3 countries with levels >0.001 μg/L. Most of them have
high solubility and low logP, indicating that preferentially they
will remain in water. Even though pharmaceuticals can be
degraded in water (Carlsson et al. 2006), their continuous
discharge, even at low concentrations, makes these drugs re-
calcitrant and environmentally hazardous compounds.
Because of the lack of a legislation that controls the levels of
drug residues in discharges and in surface waters, it is impor-
tant to prioritize actions that minimize the impact of these
pollutants on the environment. Thus, the theoretical evalua-
tion of presence and risk can provide a new and simple to use
tool to predict their presence in the environment. These
tools can be extrapolated to other areas with similar problems
(e.g., kindergartens, hospitals).
For the 12 compounds likely to be consumed in amounts
that can reach river waters, we determined the aquatic toxicity
using different organisms according to available data from the
open bibliography (Table 3). The toxicity in general is low.
However, it has been pointed out that there is scarce informa-
tion about long-term effects of pharmaceuticals to aquatic or-
ganisms, in particular with respect to biological targets (Fent
et al. 2006). In the environment, acute toxic effects of phar-
maceuticals are unlikely but chronic ecotoxicity data is needed
for a correct evaluation of risk (Carlsson et al. 2006).
Main compounds to be released from health-care institu-
tions were laxatives such as macrogol and lactitol; analgesic
and antipyretic drugs such as paracetamol and piracetam; an-
tibiotics such as amoxicillin and levofloxacin, gabapentin, and
levetiracetam for the treatment of epilepsy and neuropathic
pain; and pharmaceuticals for the treatment of diabetes (met-
formin and insulin). Prioritization according to PECs helps in
the implementation of focused monitoring programs that con-
sider only the most abundant and toxic compounds, in an
attempt to control and mitigate the release of pharmaceuticals
consumed in health care institutions.
Risk management
The new BUrban Water Agenda 2030,^ addressed at the
Leeuwarden Conference (02.2016), incorporates concerns
about wastewater treatment by focusing on emerging contam-
inants to contribute to the achievement of the good chemical
status of water bodies. The main objective is to ensure the
quality of water for urban use.
In this study, we have identified health institutions as a
point source pollution of pharmaceuticals to the environment,
with similar conclusions as those obtained in Germany
(Herrmann et al. 2015). The number of homes for elderly
people is currently high and is expected to increase in the
future. This is worrying because these establishments are a
considerable source of emerging pollutants and, hitherto, there
are no guidelines or information about the risk management
of effluents, which are typically classified as domestic.
Nonetheless, the World Health Organization (Chartier
2014) alerts that although a large part of the wastewater
from health-care facilities can be considered domestic (be-
cause they pose the same risks as domestic wastewater),
depending on the service and tasks of the facility, these
wastewaters might contribute to the contamination of rivers.
This is clearly the case for the sociosanitary centers, where the
consumption of pharmaceuticals is high.
Consequently, as for classical hospitals, risk assessments
have to be envisaged for elderly residences. Several possibil-
ities can be imagined. One of them could be the application of
the recent French guideline for good management of waste
produced by health-care establishments (edited by the
French Ministry of Health) that propose initiatives to organize
the management of liquid waste (http://social-sante.gouv.fr/
IMG/pdf/pour_une_bonne_gestion_des_dechets_produits_
par_les_etablissements_de_sante_et_medico-sociaux.pdf).
Onsite treatment could be another effective strategy to
manage the release of pharmaceuticals to the environment.
A future avenue for this area would be to conduct a cost-
benefit analysis and sociological studies to know the viability
of this strategy.
Daily practices could be also a good but challenging pro-
cedure to mitigate the release of pharmaceuticals, and this can
be done specifically for incontinency pads.
Overall risk management is a complex issue because it
involves many and different types of stakeholders, such as
environmental and health authorities, the pharmaceutical
sector, water and waste industries, health practitioners,
researchers, and elderly home managers and clients, as
well as the general public. Environmental, social, and
economic objectives have to be considered for identifying
the problem and determining the risk clearly and early in
the process, so that mitigation actions can be achieved. To
facilitate this process, risk assessment and risk manage-
ment should be integrated activities and should share a
Table 3 Physico-chemical properties of prioritized pharmaceuticals according to PEC data with values higher than 0.001 µg/L and reported aquatic toxicity (Aquatox μg/L)
Pharmaceutical* CAS num. Molecular Formula Mw Water solubility (mg/L) LogP Pv (mmHg, 25°C) Half-life Aquatic toxicity (μg/L) and tested organism
PECriv > 0.01 μg/L
Metformin 657-24-9 C4H11N5 129.2 1E+6 -2.64 7.6E-05 6.2 h 3300 D. magna, EC50, reproduction
Macrogol 25322-68-3 H–(OCH2CH2)n–OH NA 1E+5 NA NA NA >1000000 Oryzias latipes LC50; 24h
Paracetamol 103-90-2 C8H9NO2 151.2 3E+4 0.46 2E-06 1-4 h 6400 D. magna, LC50
Gabapentin 60142-96-3 C9H17NO2 171.2 4491 -1.1 3E-10 4–7 h NA
Amoxicillin 26787-78-0 C16H19N3O5S 365.4 3433 0.87 4.7e-17 1 h 10000 D. magna LC50
Acetylcysteine 616-91-1 C5H9NO3S 163.2 5090 -0.03 1.09e-05 15 d 151000 D. magna, EC50
Cyanocobalamin 68-19-9 C63H88CoN14O14P 1355.4 1.3E+4 1.87 NA 6 d 20-100 Poteriochromonas malhamensis EC50 72h
Levetiracetam 102767-28-2 C8H14N2O2 170.2 7910 -0.49 3.5E-06 6-8 h 341000 D. magna, LC50
Levofloxacin 100986-85-4 C18H20FN3O4 361.4 3E+4 -0.39 9.8E-13 6-8 h 10000 D. magna; NOEC;48h
Lactitol 585-86-4 C12H24O11 344.3 377000 -3.2 2.24E-17 2 d NA
Piracetam 7491-74-9 C6H10N2O2 142.2 8E+4 -1.54 6.4E-06 NA NA
PECriv > 0.001 <0.01 μg/L
Acetylsalicylic acid 50-78-2 C9H8O4 180.2 5295 1.19 6.6e-05 0.5 h 360314 D. pulex; LC50
Clomethiazole 533-45-9 C6H8ClNS 161.6 1041 2.83 0.0229 3.6-6 h NA
Diosmin 520-27-4 C28H32O15 608.5 407.8 0.14 6E-27 NA NA
Furosemide 54-31-9 C12H11ClN2O5S 330.7 149.3 2.03 3.1E-11 2 h 10000 Hydra vulgaris, NOEC 7d
Glucosamine 3416-24-8 C6H13NO5 179.2 1E+6 -2.2 2E-08 NA NA
Ibuprofen 15687-27-1 C13H18O2 206.3 41.05 3.97 1.9E-04 2-4 h 1600 D. magna, LC50
Levodopa 59-92-7 C9H11NO4 197.2 3E+5 -2.39 2.6E-10 1.5 h 1780000 D. magna, LC50
Megestrol 3562-63-8 C22H30O3 342.5 27.02 3.41 3.5E-10 34 h 5 D. magna, EC50
Omeprazole 73590-58-6 C17H19N3O3S 345.4 359 2.23 1.16E-11 60 d 88 D. magna, EC50
Oxerutin** 96304-71-1 C33H42O19 742.7 19300 -2.86 2.31E-34 15 d NA
Quetiapine 111974-69-7 C21H25N3O2S 383.5 40.3 2.8 2.74E-13 60 d 10-100 D. magna, EC50
Sulfamethoxazole 723-46-6 C10H1N3O3S 253.3 610 0.89 1.3E-07 37 d 3300 D. magna, EC50
Tiotropium bromide 136310-93-5 C19H22BrNO4S2 472.4 3E+4 -1.76 1.9E-18 5-6 d 69 D. magna, EC50
Troxerutin 7085-55-4 C33H42O19 742.7 2E+4 -2.86 2.3E-34 NA NA
Valproic acid 99-66-1 C8H16O2 144.2 1300 2.75 0.0847 15 d NA
*Insulin excluded as it is a peptide hormone; ** Plant constituents
common requirement which is effective risk communica-
tion (Naidu et al. 2016).
Knowledge on the risks associated with pharmaceutical
residues in wastewater is very weak, sometimes controversial,
and in part unknown (García-Santiago et al. 2016; Touraud
et al. 2011). A perception study on elderly people’s residences
is currently in progress, and the first results show a real misun-
derstanding of the problem (data not shown). Related knowl-
edge, attitudes, and social representations have yet to be
established from a social science point of view (Pidgeon et al.
2011). This elaboration process starts in the inquiries about the
topic (Lichtenstein and Slovic 2006) and the cultural and social
dispositions of people (Kahan 2009). For this reason, the risk
and benefits of pharmaceuticals, namely, openness through fre-
quent dialogs, decisions based on the best available science,
transparency, timeliness, and responsiveness, should be taken
into consideration (Bouder 2011). Furthermore, campaigns to
increase risk awareness should be initiated before any alarm
episode (Barnett and Breakwell 2003) or crisis (Gaspar et al.
2015).
Conclusions
We have identified senior residences as a source of pharma-
ceuticals to surface waters at concentrations higher than
0.01 μg/L, which is the EMA threshold for risk assessment.
Depending on the size of the elderly people’s home, and taking
into account the circumstances and medical treatments usually
received, wastewaters contain pharmaceuticals in their effluents
at concentrations of hundreds of micrograms per liter. Because
these effluents are discharged to sewerage systems andWWTP
are mostly inefficient to eliminate pharmaceuticals, residues are
discharged to river waters, thus contributing to water pollution.
This effect, amplified by the large number of residences in the
south-west Europe, indicates the importance of controlling the
discharges of pharmaceuticals form senior residences to mini-
mize the impact on aquatic ecosystems. A protocol scheme and
risk management actions foreseen should be used to implement
focused monitoring and remediation technologies that consider
the most toxic compounds to ensure effectiveness in the control
and evaluation of the impact of pharmaceuticals released from
health-care facilities.
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Pharmaceutical Family drug CODI ATC 
Disulfiram 
Alcohol 
dependence 
N07BB01; P03AA04 
Acetylsalicylic acid Analgesic A01AD05;B01AC06;N02BA01 
Codeine Analgesic R05DA04 
Fentanyl Analgesic N01AH01;N02AB03 
Glucosamine Analgesic M01AX05 
Metamizole Analgesic N02BB02 
Morphine Analgesic N02AA01 
Oxycodone Analgesic N02AA05 
Paracetamol Analgesic N02BE01 
Tapentadol Analgesic N02AX06 
Tramadol Analgesic N02AX02 
Transdermal 
Fentanyl 
Analgesic N01AH01;N02AB03 
DHEA Androgen NA 
Mepivacaine Anesthetic N01BB03 
Prilocaine Anesthetic N01BB04 
Almagate Antacid A02AD03 
Bicarbonate de 
sodium 
Antacid B05CB04; B05XA02 
Naloxone Antagonist opiates A06AH04;V03AB15 
Dimeticone Antiacid P03AX05 
Cyproterone Antiandrogen G03HA01 
Finasteride Antiandrogen D11AX10;G04CB01 
Amiodarone Antiarrhytmic C01BD01 
Digoxin Antiarrhytmic C01AA05 
Lidocaine Antiarrhytmic 
C01BB01;C05AD01;D04AB01;N01BB02;R02AD02; 
S01HA07;S02DA01 
Verapamil Antiarrhytmic C08DA01 
Formoterol Antiasthmatic R03AC13 
Ipratropium bromide Antiasthmatic R01AX03;R03BB01 
Montelukast Antiasthmatic R03DC03 
Salbutamol Antiasthmatic R03AC02;R03CC02 
Teofilline Antiasthmatic R03DA04 
Theophylline Antiasthmatic R03DA04 
Amikacin Antibiotic D06AX12;J01GB06;S01AA21 
Amoxicillin Antibiotic J01CA04 
Cefixime Antibiotic J01DD08 
Cefpodoxime Antibiotic J01DD13 
Ceftriaxone Antibiotic J01DD04 
Cefuroxime Antibiotic J01DC02;S01AA27 
Chloramphenicol Antibiotic 
D06AX02;D10AF03;G01AA05;J01BA01;S01AA01; 
S02AA01;S03AA08 
Chlortetracycline Antibiotic A01AB21;D06AA02;J01AA03;S01AA02 
Ciprofloxacin Antibiotic J01MA02;S01AE03;S02AA15;S03AA07 
Clarithromycin Antibiotic J01FA09 
Cloxacillin Antibiotic J01CF02 
Flammazine Antibiotic DB05245 
Fusidic acid Antibiotic D06AX01;D09AA02;J01XC01;S01AA13 
Gentamycin Antibiotic D06AX07;J01GB03;S01AA11;S02AA14;S03AA06 
Isoniazid Antibiotic J04AC01 
Levofloxacin Antibiotic J01MA12;S01AE05 
Metronidazole Antibiotic A01AB17;D06BX01;G01AF01;J01XD01;P01AB01 
Mupirocin Antibiotic D06AX09;R01AX06 
Neomycin Antibiotic 
A01AB08;A07AA01;B05CA09;D06AX04;J01GB05; 
R02AB01;S01AA03;S02AA07;S03AA01 
Nitrofurantoin Antibiotic J01XE01 
Nitrofural Antibiotic 
B05CA03;D08AF01;D09AA03;P01CC02;S01AX04; 
S02AA02 
Norfloxacine Antibiotic J01MA06; S01AE02 
Ofloxacine Antibiotic J01MA01;S01AE01;S02AA16 
Pristinamycin IA Antibiotic J01FG01 
Rifampicine Antibiotic J04AB02 
Rifaximin Antibiotic A07AA11;D06AX11 
Roxithromycin Antibiotic J01FA06 
Sulfamethoxazole Antibiotic J01EC01 
Tobramycin Antibiotic J01GB01;S01AA12 
Trimethoprim Antibiotic J01EA01 
Virginiamycin Antibiotic D06AX10 
Atropine sulfate Anticholinergic A03BA01 
Clidinium bromure Anticholinergic R03BB05 
Dihexazine Anticholinergic DB00434 
Glycopyrronium 
bromide 
Anticholinergic A03AB02;R03BB06 
Indacaterol maleate Anticholinergic R03AC18 
Scopolamine Anticholinergic A04AD01;N05CM05;S01FA02 
Tiotropium bromide Anticholinergic R03BB04 
Trospium Chloride Anticholinergic DB00209 
Galantamine Anticholinesterase N06DA04 
Rivastigmine Anticholinesterase N06DA03 
Acenocoumarol Anticoagulant B01AA07 
Apixaban Anticoagulant B01AF02 
Dabigatran Anticoagulant B01AE07 
Enoxaparin Sodium Anticoagulant B01AB05 
Fondaparinux Anticoagulant B01AX05 
Rivaroxaban Anticoagulant B01AF01 
Carbamazepine Anticonvulsant N03AF01 
Lamotrigine Anticonvulsant N03AX09 
Levetiracetam Anticonvulsant N03AX14 
Agomelatine Antidepressant N06AX22 
Amitriptyline Antidepressant N06AA09 
Citalopram Antidepressant N06AB04 
Duloxetine Antidepressant N06AX21 
Escitalopram Antidepressant N06AB10 
Fluvoxamine Antidepressant N06AB08 
Mianserin Antidepressant N06AX03 
Mirtazapine Antidepressant N06AX11 
Paroxetine Antidepressant N06AB05 
Reboxetine Antidepressant N06AX18 
Sertraline Antidepressant N06AB06 
Acarbose Antidiabetic A10BF01 
Gliclazide Antidiabetic A10BB09 
Glimepiride Antidiabetic A10BB12 
Glycazide Antidiabetic A10BB09 
Linagliptin Antidiabetic A10BH05 
Metformin Antidiabetic A10BA02 
Repaglinide Antidiabetic A10BX02 
Saxagliptin Antidiabetic A10BH03 
Sitagliptin Antidiabetic A10BH01 
Vildagliptin Antidiabetic A10BH02 
Loperamide Antidiarrhea A07DA03 
Racecadotril Antidiarrhea A07XA04 
Domperidone Antiemetic A03FA03 
Clonazepam Antiepileptic N03AE01 
Gabapentin Antiepileptic N03AX12 
Oxcarbazepine Antiepileptic N03AF02 
Phenobarbital Antiepileptic N03AA02 
Phenytoin Antiepileptic N03AB02 
Pregabalin Antiepileptic N03AX16 
Primidone Antiepileptic N03AA03 
Topiramate Antiepileptic N03AX11 
Valproic Acid Antiepileptic N03AG01 
Tamoxifen Antiestrogen L02BA01 
Tranexamique Antifibrinolytic B02AA02 
Ciclopirox Antifungal D01AE14;G01AX12 
Clotrimazol Antifungal A01AB18;D01AC01;G01AF02 
Fluconazole Antifungal D01AC15;J02AC01 
Ketoconazole Antifungal D01AC08;G01AF11;J02AB02 
Miconazole Antifungal A01AB09;A07AC01;D01AC02;G01AF04;J02AB01;S02AA13 
Nystatin Antifungal A07AA02;D01AA01;G01AA01 
Brimonidine 
Anti-glaucoma 
agent 
D11AX21;S01EA05 
Dorzolamide 
Anti-glaucoma 
agent 
S01EC03 
Latanoprost 
Anti-glaucoma 
agent 
S01EE01 
Travoprost 
Anti-glaucoma 
agent 
S01EE04 
Alimemazine Antihistaminic R06AD01 
Aminophylline Antihistaminic R03DA05 
Cetirizine Antihistaminic R06AE07 
Dimenhydrinate Antihistaminic NA 
Ebastine Antihistaminic R06AX22 
Hydroxyzine Antihistaminic N05BB01 
Olodaterol Antihistaminic R03AC19 
Ranitidine Antihistaminic A02BA02 
Rupatadine Antihistaminic R06AX28 
Salmeterol Antihistaminic R03AC12 
Aliskiren Antihypertensive C09XA02 
Amlodipine Antihypertensive C08CA01 
Candesartan Antihypertensive C09CA06 
Captopril Antihypertensive C09AA01 
Cilazapril Antihypertensive C09AA08 
Enalapril Antihypertensive C09AA02 
Felodipine Antihypertensive C08CA02 
Hydralazine Antihypertensive C02DB02 
Indapamide Antihypertensive C03BA11 
Irbesartan Antihypertensive C09CA04 
Lercanidipine Antihypertensive C08CA13 
Lisinopril Antihypertensive C09AA03 
Losartan Antihypertensive C09CA01 
Nicardipine Antihypertensive C08CA04 
Nifedipine Antihypertensive C08CA05 
Olmesartan Antihypertensive C09CA08 
Perindopril Antihypertensive C09AA04 
Ramipril Antihypertensive C09AA05 
Telmisartan Antihypertensive C09CA07 
Urapidil Antihypertensive C02CA06 
Valsartan Antihypertensive C09CA03 
Zofenopril Antihypertensive C09AA15 
Betamethasone Anti-inflammatory 
A07EA04;C05AA05;D07AC01;D07XC01;H02AB01; 
R01AD06;R03BA04;S01BA06;S01CB04;S02BA07; 
S03BA03 
Budesonide Anti-inflammatory A07EA06;D07AC09;R01AD05;R03BA02 
Colchicine Anti-inflammatory M04AC01 
Deflazacorte 
(Rosilan) 
Anti-inflammatory H02AB13 
Dexamethasone Anti-inflammatory 
A01AC02;C05AA09;D07AB19;D07XB05;D10AA03; 
H02AB02;R01AD03;S01BA01;S01CB01;S02BA06; 
S03BA01 
Mesalazine Anti-inflammatory A07EC02 
Methylprednisolone Anti-inflammatory D07AA01;D10AA02;H02AB04 
Nimesulide Anti-inflammatory M01AX17;M02AA26 
Sulfasalazine Anti-inflammatory A07EC01 
Quinine Antimalarial P01BC01 
Letrozole Antineoplasic L02BG04 
Benserazide Antiparkinsonian NA 
Biperiden Antiparkinsonian N04AA02 
Bromocriptine 
(Parlodel) 
Antiparkinsonian G02CB01;N04BC01 
Buprenorphine Antiparkinsonian N02AE01;N07BC01 
Carbidopa Antiparkinsonian NA 
Levodopa Antiparkinsonian N04BA01 
Pramipexole Antiparkinsonian N04BC05 
Ropinirole LP Antiparkinsonian N04BC04 
Selegiline Antiparkinsonian N04BD01 
Clopidogrel Antiplatelet agent B01AC04 
Dipyridamole Antiplatelet agent B01AC07 
Ticlopidine Antiplatelet agent B01AC05 
Amisulpride Antipsychotic N05AL05 
Chlorpromazine Antipsychotic N05AA01 
Clotiapine Antipsychotic N05AH06 
Clozapine Antipsychotic N05AH02 
Cyamemazine Antipsychotic N05AA06 
Fluphenazine Antipsychotic N05AB02 
Haloperidol Antipsychotic N05AD01 
Melperone Antipsychotic N05AD03 
Olanzapine Antipsychotic N05AH03 
Paliperidone Antipsychotic N05AX13 
Zuclopenthixol 
decanoate 
Antipsychotic N05AF05 
Chlorhexidine Antiseptic 
A01AB03;B05CA02;D08AC02;D09AA12;R02AA05; 
S01AX09;S02AA09;S03AA04 
Povidone Antiseptic 
D08AG02;D09AA09;D11AC06;G01AX11;R02AA15; 
S01AX18 
Butylscopolamine Antispasmodic A03BB01 
Fesoterodine Antispasmodic G04BD11 
Mebeverine Antispasmodic A03AA04 
Oxybutynin Antispasmodic G04BD04 
Phloroglucinol Antispasmodic A03AX12 
Solifenacin Antispasmodic G04BD08 
Trimebutine Antispasmodic A03AA05 
Trimethylphloroglucin
ol 
Antispasmodic A03AX12 
Warfarine Antithrombotic B01AA03 
Carbimazole Antithyroid H03BB01 
Cloperastine Antitusive R05DB21 
Dextromethorphan Antitusive R05DA09 
Cinitapride Antiulcer A03FA08 
Esomeprazole Antiulcer A02BC05 
Lansoprazole Antiulcer A02BC03 
Omeprazole Antiulcer A02BC01 
Pantoprazole Antiulcer A02BC02 
Rabeprazole Antiulcer A02BC04 
Sucralfate Antiulcer A02BX02 
Betahistine Antivertiginous N07CA01 
Flunarizine Antivertiginous N07CA03 
Aciclovir Antiviral D06BB03;J05AB01;S01AD03 
Amantadine Antiviral N04BB01 
Alprazolam Anxiolitic N05BA12 
Bromazepam Anxiolitic N05BA08 
Buspirone Anxiolitic N05BE01 
Chlordiazepoxide Anxiolitic N05BA02 
Clorazepate Anxiolitic N05BA05 
Clotiazepam Anxiolitic N05BA21 
Cloxazolam Anxiolitic N05BA22 
Diazepam Anxiolitic N05BA01 
Ethyl Loflazepate Anxiolitic N05BA18 
Lorazepam Anxiolitic N05BA06 
Lormetazepam Anxiolitic N05CD06 
Mexazolam Anxiolitic NA 
Midazolam Anxiolitic N05CD08;N05CD08 
Nordazepam Anxiolitic N05BA16 
Oxazepam Anxiolitic N05BA04 
Quetiapine 
Atypical 
antipsychotic 
N05AH04 
Flumazenil 
Benzodiazepine 
antagonist 
V03AB25 
Clavulanic acid 
Beta-lactamase 
inhibitor 
NA 
Ivabradine Bradycard C01EB17 
Terbutaline Bronchodilator R03AC03;R03CC03 
Diltiazem 
Calcium channel 
blockers 
C05AE03;C08DB01 
Epinephrine 
hydrochlorure 
Cardiac stimulant R01AA14 
Anethole trithione Choleretic A16AX02 
Clostridiopeptidase Collagenase NA 
Prednisone Corticosteroid A07EA03;H02AB07 
Altizide Diuretic C03EA04 
Bumetanide Diuretic C03CA02 
Chlortalidone Diuretic C03BA04 
Eplerenone Diuretic C03DA04 
Furosemide Diuretic C03CA01 
Hydrochlorothiazide Diuretic C03AA03 
Metolazone Diuretic C03BA08 
Spironolactone Diuretic C03DA01 
Lactilol Edulcorant A06AD12 
Hypromellose Eye Drops S01KA02 
Beclomethasone 
dipropionate 
Glucocorticoid A07EA07 
Silymarin Hepatoprotective A05BA03 
Desloratadine 
Histamine 
antagonist 
R06AX27 
Clomethiazole Hypnotic N05CM02 
Estazolam Hypnotic N05CD04 
Flurazepam Hypnotic N05CD01 
Melatonin Hypnotic N05CH01 
Zolpidem Hypnotic N05CF02 
Alendronic acid Hypocalcemic M05BA04 
Ibandronic acid Hypocalcemic M05BA06 
Atorvastatin Hypolipidemic C10AA05 
Fenofibrate Hypolipidemic C10AB05 
Fluvastatin Hypolipidemic C10AA04 
Gemfibrozil Hypolipidemic C10AB04 
Pitavastatin Hypolipidemic C10AA08 
Pravastatin Hypolipidemic C10AA03 
Simvastatin Hypolipidemic C10AA01 
Allopurinol Hypo-uricemic M04AA01 
Acitretin Keratolytic D05BB02 
Carbomer 
Lacrymal 
substitute 
NA 
Carboxymethyl 
cellulose (CMC) 
Lacrymal 
substitute 
NA 
Chondroitin sulfate 
Lacrymal 
substitute 
M01AX25 
Bisacodyl Laxative A06AB02;A06AG02 
Lactulose Laxative A06AD11 
Macrogol Laxative A06AD15 
Sene Laxative NA 
Sodium picosulfate Laxative A06AB08 
Acetylcysteine Mucolytic R05CB01;S01XA08;V03AB23 
Baclofen Muscle-relaxant M03BX01 
Thiocolchicoside Myorelaxant M03BX05 
Tizanidine Myorelaxant M03BX02 
Levomepromazine Neuroleptics N05AA02 
Metoclopramide Neuroleptics A03FA01 
Risperidone Neuroleptics N05AX08 
Sulpiride Neuroleptics N05AL01 
Tiapride Neuroleptics N05AL03 
Rosuvastatin Normolipemic C10AA07 
Dexibuprofen NSAID M01AE14 
Dexketoprofen NSAID M01AE17;M02AA27 
Diclofenac NSAID D11AX18;M01AB05;M02AA15;S01BC03 
Ibuprofen NSAID C01EB16;G02CC01;M01AE01;M02AA13;R02AX02 
Ketoprofen NSAID M01AE03;M02AA10 
Nabumetone NSAID M01AX01 
Aluminium hydroxide Others A02AB01 
Aspartic acid Others NA 
Bassorina (gomme 
de Bassorah) 
Others NA 
Calcium Others A12A;A12AA 
Calcium carbonate Others A02AC01;A12AA04 
Calcium dobesilate Others C05BX01 
Calcium Folinate Others V03AF03 
Calcium Hydrogen 
Phosphate 
Others NA 
Copper sulfate Others V03AB20 
Dry extract of 
valerian root 
Others N05CM09 
Ferrimanitol Others NA 
Ferroglycine Others NA 
Ferrous lactate Others B03AA 
Ferrous sulphate Others B03AA07 
Glucagon Others H04AA01 
Glucose Others B05CX01;V04CA02;V06DC01 
Hydrochloride Others NA 
Hydrogenocarbonate 
potassique 
Others NA 
Hydroxiethylamidon Others NA 
Hydroxypropylmethyl
cellulose 
Others S01KA02 
Lithium carbonate Others N05AN01 
Lysine 
acetylsalicylate 
Others NA 
Magnesium Others A12CC 
Pancreatin Others A09AA02 
Polystyrene Calcium 
Sulphonate 
Others V03AE01 
Potassium chloride Others A12BA01;B05XA01 
Pyrenexine Others NA 
Salicylate methyl Others NA 
Silver nitrate Others D08AL01 
Sodium bicarbonate Others B05CB04;B05XA02 
Sodium chloride Others A12CA01;B05CB01;B05XA03 
Insulin 
Pancreatic 
hormone 
A10AB01;A10AC01;A10AD01;A10AE01;A10AF01 
Isophane insulin 
Pancreatic 
hormone 
NA 
Centella asiatique Phytotherapy NA 
Plantago Phytotherapy A06AC01 
Serenoa repens Phytotherapy N05BA04 
Valerianae radix Phytotherapy N05CM09 
Triflusal 
Platelet 
aggregation 
inhibitor 
B01AC18 
Donepezil Psychoanaleptic N06DA02 
Memantine Psychoanaleptic N06DX01 
Piracetam Psychostimulant N06BX03 
Caffeine Psychotropic N06BC01 
Fluoxetine Psychotropic N06AB03 
Opium Psychotropic A07DA02;N02AA02 
Venlafaxine Psychotropic N06AX16 
Bálsamo opodeldoch Rheumatology NA 
Arcoxia (Etoricoxib) SAID M01AH05 
Etoricoxib SAID M01AH05 
Fluticasone SAID D07AC17;R01AD08;R03BA05 
Prednisolone SAID 
A07EA01;C05AA04;D07AA03;D07XA02;H02AB06; 
R01AD02;S01BA04;S01CB02;S02BA03;S03BA02 
Triamcinolone 
acetonide 
SAID A01AC01;C05AA12;D07AB09;D07XB02;H02AB08 
Zinc oxyde Skin portector NA 
Megestrol acetate Steroidal progestin G03AC05 
Midodrine Sympathomimetic C01CA17 
Levothyroxine Thyroid hormone H03AA01 
Alcaphor Urinary alkalinizer NA 
Diosmin Vasculoprotector C05CA03 
Fraction flavonoique Vasculoprotector NA 
Hesperidin Vasculoprotector NA 
Hidrosmin Vasculoprotector C05CA05 
Ginkgo biloba Vasodilator N06DX02 
Glyceryl trinitrate Vasodilator C01DA02;C05AE01 
Heptaminol Vasodilator C01DX08 
Isosorbide dinitrate Vasodilator C01DA08;C05AE02 
Naftidrofuryl Vasodilator C04AX21 
Nicorandil Vasodilator C01DX16 
Pentoxifylline Vasodilator C04AD03 
Trimetazidine Vasodilator C01EB15 
Vinpocetine Vasodilator N06BX18 
Troxerutin Vasoprotector C05CA04 
Ascorbic acid Vitamin G01AD03;S01XA15 
Calcifediol Vitamin A11CC06 
Calcipotriol hydrate 
(Daivobet) 
Vitamin D05AX02 
Calcitriol Vitamin A11CC04;D05AX03 
Calcium 
Pantothenate 
Vitamin A11HA31;D03AX04 
Cobalamin Vitamin B03BA04 
Colecalciferol Vitamin A11CC05 
Cyanocobalamin Vitamin B03BA01 
D vitamin Vitamin NA 
Folic acid Vitamin B03BB01 
Nicotinamide Vitamin A11HA01 
Phytomenadione (vit 
K1) 
Vitamin B02BA01 
Pyridoxine Vitamin A11HA02 
Riboflavine (vit B) Vitamin A11HA04 
Thiamine Vitamin A11DA01 
Vitamin C Vitamin NA 
Vitamin B9 Vitamin A11HA05 
Alpha-tocopherol, 
acetate 
Vitamin NA 
Alfuzosin α-blokers G04CA01 
Doxazosin α-blokers C02CA04 
Dutasteride α-blokers G04CB02 
Silodosin α-blokers G04CA04 
Tamsulosin α-blokers G04CA02 
Acebutolol β-blokers C07AB04 
Atenolol β-blokers C07AB03 
Bimatoprost β-blokers S01EE03 
Bisoprolol β-blokers C07AB07 
Carvedilol β-blokers C07AG02 
Métoprolol β-blokers C07AB02 
Nebivolol β-blokers C07AB12 
Propanolol β-blokers C07AA05 
Timolol β-blokers C07AA06;S01ED01 
 
 
Table SI2. Mode of action of the 24 prioritized pharmaceuticals, which can affect aquatic 
organisms.  
Compound  Mode of action 
Acetylsalicylic acid 
block of the production of prostaglandins by inhibiting 
cyclooxygenase  
Amoxicillin 
inactivation of the bacterial transpeptidase (lead to bacterial cell 
death) 
Carbidopa inhibition of the peripheral  L-dopa decarboxylase 
Ceftriaxone 
binds to carboxypeptidases, endopeptidases, and 
transpeptidases in the bacterial cytoplasmic membrane  
Ciprofloxacin 
inhibition DNA replication, transcription, repair, strand 
supercoiling repair, and recombination 
Cyanocobalamin (vitB12) cofactor methionine synthase and metylmalonyl coA mutase 
Diosmin 
decreasing of  vascular Noradrenalin degradation (by COMT 
inhibition) 
Furosemide (Lasix) 
inhibits water reabsorption in the nephron by blocking the 
sodium-potassium-chloride cotransporter (NKCC2) in the thick 
ascending limb of the loop of Henle 
Gabapentin 
increasing synaptic concentration of GABA by interaction with 
cortical neurons at voltage-sensitive calcium-channels 
Gentamicin binding to specific 30S-subunit proteins and 16S rRNA 
Glucosamine 
precursor in the biochemical synthesis of glycosylated proteins 
and lipids 
Ibuprofen 
non-selective inhibition of cyclooxygenase (decreases the 
synthesis of prostaglandins involved in mediating inflammation, 
pain, fever and swelling) 
Levetiracetam 
stimulation of  synaptic vesicle protein 2A (SV2A), inhibiting 
neurotransmitter release 
Levodopa (Sinemet) 
dopamine's precursor (small percentage of each levodopa dose 
crosses the blood-brain barrier and is decarboxylated to 
dopamine) 
Levofloxacin inhibition of bacterial DNA replication and transcription  
Macrogol   
osmotic agent, causing excess water to be retained in the stool, 
stimulating a bowel movement 
Megestrol 
progestin antitumour: suppression of luteinizing hormone by 
inhibition of pituitary function; mechanism by which produces 
effects in anorexia and cachexia: unknown. 
Metformin 
activation of AMP-activated protein kinase (AMPK) (decreasing 
blood glucose levels ) 
Oxerutine Not found 
Paracetamol 
inhibition both isoforms of cyclooxygenase, COX-1, COX-2, and 
COX-3 enzymes involved in prostaglandin (PG) synthesis 
Piracetam nootropic drug, stimulation of ADP to ATP convertion 
Pregabalin 
binding to the alpha2-delta site (an auxiliary subunit of voltage-
gated calcium channels) 
Tiotropium bromide 
(Spiriva) 
muscarinic receptor antagonist (it acts mainly on M3 muscarinic 
receptors, producing a bronchodilatory effect) 
Troxerutin venotonic and angioprotective properties 
Acetylsalicylic acid 
block of the production of prostaglandins by inhibiting 
cyclooxygenase  
Amoxicillin inactivation of the bacterial transpeptidase (bacterial cell death) 
Carbidopa inhibition of the peripheral  L-dopa decarboxylase 
Ceftriaxone 
binds to carboxypeptidases, endopeptidases, and 
transpeptidases in the bacterial cytoplasmic membrane  
Ciprofloxacin 
inhibition DNA replication, transcription, repair, strand 
supercoiling repair, and recombination 
Cyanocobalamin (vitB12) cofactor methionine synthase and metylmalonyl coA mutase 
Diosmin 
decreasing of  vascular Noradrenalin degradation (by COMT 
inhibition) 
